Article information
Full text is only aviable in PDF
Bibliografía
[1.]
International Consensus Report on the diagnosis and management of, asthma.
Clin Exp Allergy, 22 (1992), pp. 1-72
[3.]
Global Initiative for asthma.
Global strategy for asthma management and prevention.
National Heart, Lung and Blood Institute, (1995),
[4.]
A.J. Roncoroni, E. Abbate, J.C. Figueroa Casas, R. Gené, N. Martelli, S. Quadrelli, et al.
Normas para el tratamiento del asma bronquial.
Medicina, 53 (1993), pp. 249-259
[5.]
M.R. Sears, D.R. Taylor, C.G. Pring, D.C. Lake, Q.Q. Li, E.M. Flannery, et al.
Regular inhaled beta-agonist treatment in bronchial asthma.
Lancet, 336 (1990), pp. 1391-1396
[6.]
D.R. Taylor, M.R. Sears, G.P. Herbison, E.M. Flannery, C.G. Print, D.C. Lake, et al.
Regular inhaled beta agonist in asthma: effects of exacerbations and lung function.
Thorax, 48 (1993), pp. 134-138
[7.]
G.F. Alvine, P. Rodgers, K.M. Fitzsimmons, B.C. Abreus.
Disposable jet nebulizer: how reliable are they?.
Chest, 101 (1991), pp. 316-319
[8.]
S.P. Newman.
Aerosol deposition considerations in inhalation therapy.
Chest, 88 (1985), pp. 152-160
[9.]
C.M. Kim, D. Trujillo, M.A. Sackner.
Size aspects of metered dose inhaler aerosols.
Am Rev Respir Dis, 132 (1985), pp. 137-142
[10.]
S.P. Newman, A.B. Millar, T.R. Lennard Jones, F. Morén, S.W. Clarke.
Improvement of pressurized aerosol deposition with Nebuhaler spacer device.
Thorax, 39 (1984), pp. 935-941
[11.]
K. Blake, M. Hoppe, E. Harman, L. Hendeless.
Relative amount of albuterol delivered to lung receptors from metered dose inhaler and nebulizer solution.
Chest, 101 (1992), pp. 309-315
[12.]
A. Colacone, M. Afilalo, N. Wolkove, H.A. Kreisman.
Comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma.
Chest, 104 (1993), pp. 835-841
[13.]
G. Rodrigo, C. Rodrigo.
Comparison of saltutamol delivered by nebulizer or metered dose inhaler with a pear shaped spacer in acute asthma.
Curr Ther Res, 54 (1993), pp. 797-807
[14.]
B.J. Lipworth, A.D. Struthers, D.G. McDevitt.
Tachyphylaxis to systemic but not to airway responses during prolonted therapy with high dose inhaled salbutamol in asthmatic.
Am Rev Respir Dis, 140 (1989), pp. 586-592
[15.]
R.Y. Lin, A.J. Smith, P. Horgenroeder.
High serum albuterol levels and tachycardia in adult asthmatics treated with high dose continuosly aerosolized albuterol.
Chest, 103 (1983), pp. 221-225
[16.]
C. Rodrigo, G. Rodrigo.
High dose MDI salbutamol treatment of asthma in the ED.
Am J Emerg Med, 13 (1995), pp. 21-26
[17.]
C. Rodrigo, G. Rodrigo.
Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered dose inhaler with a spacer.
Chest, 106 (1994), pp. 1071-1076
[18.]
C. Rodrigo, G. Rodrigo.
Early administration of hydrocortisone in the emergency room treatment of acute asthma: a controlled clinical trial.
Respir Med, 88 (1994), pp. 1-7
[19.]
M.A. Higham, A.M. Sharara, P. Wilson, R.J. Jenkins, G.A. Glendenning, P.W. Ind.
Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
Thorax, 52 (1997), pp. 975-980
[20.]
G. Di Lorenzo, G. Morici, F. Norrito, P. Mansueto, M. Melluso, D. Purello, et al.
Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.
Clin Exp Allergy, 5 (1995), pp. 951-956
[21.]
D.S. Pearlman, P. Chervinsky, C. LaForce, J.M. Seltzer, D.L. Southern, J.P. Kemp, et al.
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.
N Engl J Med, 327 (1992), pp. 1420-1425
[22.]
G.E. Dalonzo, R.A. Nathan, S. Henochowicz, R.J. Morris, P. Ratner, S.I. Rennard.
Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
JAMA, 271 (1994), pp. 1412-1416
[23.]
A. Ullman, J. Hedner, N. Svedmyr.
Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis.
Am Rev Respir Dis, 142 (1990), pp. 571-575
[24.]
C.K. Lai, C.H. Chan, S.S. Ho, A.C. Hui, K.N. Lai.
Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids.
Chest, 108 (1995), pp. 36-40
[25.]
D.S. Pearlman.
Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy.
Ann Allergy Asthma Immunol, 75 (1995), pp. 180-184
[26.]
E.F. Juniper, P.R. Johnston, C.M. Borkhoff, G.H. Guyatt, L.P. Boulet, A. Haukioja.
Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.
Am J Respir Crit Care Med, 151 (1995), pp. 66-70
[27.]
B.D. Hermansson, R.J. Jenkins.
A 4-week comparison of salmeterol and terbutaline in adult asthma.
Allergy, 50 (1995), pp. 551-558
[28.]
P. Leblanc, A. Kinght, H. Kreisman, C.M. Borkhoff, P.R. Johnston.
A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma.
Am J Respir Crit Care Med, 154 (1996), pp. 324-328
[29.]
P. Faurschou, I. Steffensen, L. Jacques.
Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids.
Eur Respir J, 9 (1996), pp. 1885-1890
[30.]
M.G. Britton, J.S. Earnshaw, J.B. Palmer.
A twleve month comparison of salmeterol with salbutamol in asthmatic patients.
Eur Respir J, 5 (1992), pp. 1062-1067
[31.]
B. Lundback, D.W. Rawlinson, J.B. Palmer.
Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients.
Thorax, 48 (1993), pp. 148-153
[32.]
W. Castle, R. Fuller, J. Hall, J. Palmer.
Serevent nationwide surveillande study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.
Br Med J, 306 (1993), pp. 1034-1037
[33.]
H. Hendenström, T. Wegener, G. Boman, L. Wåhlander, B. Melander.
Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma.
Allergy, 47 (1992), pp. 158-163
[34.]
A.P. Sykes, J.G. Ayres.
A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma.
Respir Med, 84 (1990), pp. 135-138
[35.]
A.B. Becker, F.E. Simons.
Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma.
Lung, 168 (1990), pp. 99-102
[36.]
R. Kozlik Feldmann, A. Von Berg, D. Berdel, D. Reinhardt.
Longterm effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocites in children with bronchial asthma.
Eur J Med Res, 10 (1996), pp. 465-470
[37.]
A. Wallin, B. Melander, L. Rosenhall, T. Sandström, L. Wåhlander.
Formoterol, a new long acting beta 2 agonist for inhalation twide daily, compared with salbutamol in the treatment of asthma.
Thorax, 45 (1990), pp. 259-261
[38.]
S. Kesten, K.R. Chapman, I. Broder, A. Cartier, R.H. Hyland, A. Knight, et al.
A three-month comparison of twice dily inhaled formoterol versus four times dily inhaled albuterol in the management of stable asthma.
Am Rev Respir Dis, 144 (1991), pp. 622-625
[39.]
P. Arvidsson, S. Larsson, C.G. Löfdahl, B. Melander, N. Svedmyr, L. Wåhlander.
Inhaled formoterol during one year in asthma: a comparison with salbutamol.
Eur Respir J, 4 (1991), pp. 1168-1173
[40.]
P.R. Hekking, F. Maesen, A. Greefhorst, J. Prins, Y. Tan, P. Zweers.
Long-term efficacy of formoterol compared to salbutamol.
Lung, 168 (1990), pp. 76-82
[41.]
H.Y. Lau, P.L. Wong, C.K. Lai, J.K. Ho.
Effects of long-acting beta 2-adrenoceptor agonists on mast cells on rat, guinea pig and human.
Int Arch Allergy Immunol, 105 (1994), pp. 177-180
[42.]
P.R. Butchers, C.J. Vardey, M. Johnson.
Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung.
Br J Pharmacol, 104 (1991), pp. 672-676
[43.]
C.J. Whelan, M. Johnson, C.J. Vardey.
Comparison of the anti-inflammatory properties of formoterol. Salbutamol and salmeterol in guinea-pig skin and lung.
Br J Pharmacol, 110 (1993), pp. 613-618
[44.]
C.J. Whelan, M. Johnson.
Inhibition by salmeterol of increase vascular permeability and granulocyte accumulation in guinea-pig lung and skin.
Br J Pharmacol, 105 (1992), pp. 831-838
[45.]
I. Erjefält, C.G. Persson.
Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways.
Am Rev Respir Dis, 144 (1991), pp. 788-791
[46.]
J.J. Bowden, I. Sulakvelidze, D.M. McDonald.
Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol.
J Appl Physiol, 77 (1994), pp. 397-405
[47.]
H. Inoue, H. Aizawa, K. Matsumoto, M. Shigyo, S. Takata, M. Hara, et al.
Effect of beta 2-agonists on histamine-induced airway microvascular keakage in ozone-exposed guinea pigs.
Am J Respir Crit Care Med, 156 (1997), pp. 723-727
[48.]
C. Advenier, Y. Quian, J.D. Koune, M. Molimard, M.L. Candenas, E. Naline.
Formoterol and salbutamol inhibit bradykinin– and histamine-induced airway microvascular leakage in guinea-pig.
Br J Pharmacol, 105 (1992), pp. 792-798
[49.]
J.J. Bowden, I. Sulakvelidze, D.M. McDonald.
Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol.
J Appl Physiol, 77 (1994), pp. 397-405
[50.]
A.J. Baker, J. Palmer, M. Johnson, R.W. Fuller.
Inhibitory actions of salmeterol on human airway macrophages and blood monocytes.
Eur J Pharmacol, 264 (1994), pp. 301-306
[51.]
B. Pedersen, R. Dahl, B.B. Larsen, P. Venge.
The effect of salmeterol on the early– and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X.
Allergy, 48 (1993), pp. 377-382
[52.]
P.V. Gardiner, C. Ward, H. Booth, A. Allison, D.J. Hendrick, E.H. Walters.
Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics.
Am J Respir Crit Care Med, 150 (1994), pp. 1006-1011
[53.]
M. Kraft, S.E. Wenzel, C.M. Bettinger, R.J. Martin.
The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.
Chest, 111 (1997), pp. 1249-1254
[54.]
M.M. Pizzichini, J.C. Kidney, B.J. Wong, M.M. Morris, A. Efhimiadis, J. Dolovich, et al.
Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses.
Eur Respir J, 9 (1996), pp. 449-455
[55.]
D.H. Yates, S.A. Kharitonov, P.J. Barnes.
Effect of short– and longacting inhaled beta2-agonists on exhaled nitric oxid in asthmatic patients.
Eur Respir J, 10 (1997), pp. 1483-1488
[56.]
L. Ramage, I.A. Cree, D.P. Dhillon.
Comparison of salmeterol with placebo in mild asthma: effect on perpheral blood phagocyte function and cytokine levels.
Int Arch Allergy Immunol, 105 (1994), pp. 181-184
[57.]
J.A. Roberts, P. Bradding, A.F. Walls.
The effect of salmeterol xinafoate on lavage findings in asthma.
Am Rev Respir Dis, 145 (1992), pp. A418
[58.]
B.J. Wong, J. Dolovich, E.H. Ramsdale, P. O’Byrne, L. Gontovnick, J.A. Denburg, et al.
Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses.
Am Rev Respir Dis, 146 (1992), pp. 1156-1160
[59.]
J. Crane, N. Pearce, A. Flatt, C. Burgess, R. Jackson, T. Kwong, et al.
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.
Lancet, 1 (1989), pp. 917-922
[60.]
W.O. Spitzer, S. Suissa, P. Ernst, R.I. Horwitz, B. Habbick, D. Cockcorft, et al.
The use of beta-agonists and the risk of death and near death from asthma.
N Engl J Med, 326 (1992), pp. 501-506
[61.]
A.J. Roncoroni, S.A. Quadrelli.
Tolerancia o resistencia a los broncodilatadores.
Medicina, 54 (1994), pp. 277-280
[62.]
H.S. Nelson, D. Raine Jr., H.C. Doner, W.C. Posey.
Subsensitivity to the bronchodilator action of albuterol procuded by chronic administration.
Am Rev Respir Dis, 116 (1977), pp. 871-878
[63.]
M.L. Brandon.
Long-term study comparing fenoterol and isoproterenol inhalation in asthmatic patients.
Ann Allergy, 40 (1978), pp. 86-93
[64.]
P. Chervinsky.
The development of drug tolerance during longterm beta2-agonist bronchodilator therapy.
Chest, 73 (1978), pp. 1001-1002
[65.]
G.N. Beall, S.N. Steen, J. Kuo, R. Smith.
A three month study of the bronchodilator effects of aerosolized fenoterol and isoproterenol.
Chest, 73 (1978), pp. 996-997
[66.]
S.T. Holgate, C.J. Baldwin, A.E. Tattersfield.
Beta-adrenergic agonist resistance in normal human airway.
Lancet, 2 (1977), pp. 375-377
[67.]
E.T. Peel, G.J. Gibson.
Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine.
Am Rev Respir Dis, 121 (1980), pp. 973-978
[68.]
C.P. Van Schayck, S.J. Gaafsma, M.B. Visch, E. Dompeling, C. Van Weel, C.L. Van Herwaarden.
Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.
J Allergy Clin Immunol, 86 (1990), pp. 793-800
[69.]
B.J. O’Connor, S.L. Aikman, P.J. Barnes.
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma.
N Engl J Med, 327 (1992), pp. 1204-1208
[70.]
T. Haahtela, M. Järvinen, T. Kava, K. Kiviranta, S. Koskinen, K. Lehtonen, et al.
Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.
N Engl J Med, 325 (1991), pp. 388-392
[71.]
H.A. Kerstjens, P.L. Brand, M.D. Hughes, N.J. Robinson, D.S. Postma, H. Sluiter, et al.
A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group.
N Engl J Med, 327 (1992), pp. 1413-1419
[72.]
E.R. McFadden Jr..
The beta 2-agonist controversy revisited.
Ann Allergy Asthma Immunol, 75 (1995), pp. 173-176
[73.]
J.M. Drazen, E. Israel, H.A. Boushey, V.M. Chinchilli, J.V. Fahy, et al.
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma.
N Engl J Med, 335 (1996), pp. 841-846
[74.]
A. Grove, B.J. Lipworth.
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients.
Lancet, 346 (1995), pp. 201-206
[75.]
J. Lötvall, H. Lunde, A. Ullman, H. Törnqvist, N. Svedmyr.
Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells.
Allergy, 47 (1992), pp. 477-483
[76.]
D.E. Drotar, E.E. Davis, D.W. Cockcroft.
Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily.
Ann Allergy Asthma Immunol, 80 (1998), pp. 31-34
[77.]
S. Karla, V.A. Swystun, R. Bhagat, D.W. Cockcroft.
Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Chest, 109 (1996), pp. 953-956
[78.]
D.H. Yatew, S.A. Kharitonov, P.J. Barnes.
An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.
Am J Respir Crit Care Med, 154 (1996), pp. 1603-1607
[79.]
H. Booth, R. Bish, J. Walters, F. Whitehead, E.H. Walters.
Salmeterol tachyphylaxis in steroid treated asthmatic subjects.
Thorax, 51 (1996), pp. 1100-1104
[80.]
D. Cheung, M.C. Timmers, A.H. Zwinderman, E.H. Bel, J.M. Dijkman, P.J. Sterk.
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.
N Engl J Med, 327 (1992), pp. 1198-1203
[81.]
Rosenthal R, Chervincky P, DeGraff A, et al. Long term regular treatment with salmeterol is effective in protecting against bronchial hyperresponsiveness as measured by metacholine challenge in asthmatics. J Allergy Clin Immunol 99: S323.
[82.]
F.E. Simons, T.V. Gerstner, M. Cheang.
Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.
Pediatrics, 99 (1997), pp. 655-659
[83.]
L. Ramage, B.J. Lipworth, C.G. Ingram, I.A. Cree, D.P. Dhillon.
Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol.
Respir Med, 88 (1994), pp. 363-368
[84.]
D. Giannini, A. Carletti, F.L. Dente, E. Bacci, A. Di Franco, B. Vagaggini, et al.
Tolerance to the protective effect of salmeterol on allergen challenge.
Chest, 110 (1996), pp. 1452-1457
[85.]
D.H. Yates, M. Worsdell, P.J. Barnes.
Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma.
Am J Respir Crit Care Med, 156 (1997), pp. 988-991
[86.]
D.M. Newnham, D.G. McDevitt, B.J. Lipworth.
Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma.
Am J Med, 97 (1994), pp. 29-37
[87.]
D.M. Newnham, A. Grove, D.G. McDevitt, B.J. Lipworth.
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.
Thorax, 50 (1995), pp. 497-504
[88.]
K.S. Tan, A. Grove, A. McLean, Y. Gnosspelius, I.P. Hall, B. Lipworth.
Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients.
Am J Respir Crit Care Med, 156 (1997), pp. 28-35
[89.]
K.S. Tan, I.P. Hall, J. Dewar, E. Dow, B. Lipworth.
Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.
Lancet, 350 (1997), pp. 995-999
[90.]
I. Aziz, I.P. Hall, L.C. McFarlane, B.J. Lipworth.
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
J Allergy Clin Immunol, 101 (1998), pp. 337-341
[91.]
R.D. Mann, K. Kubota, G. Pearce, L. Wilton.
Salmeterol: a study by prescription-event monitoring in a UK cohort of 15.407 patients.
J Clin Epidemiol, 49 (1996), pp. 247-250
[92.]
C.G. Lofdahl, N. Svedmyr.
Beta-agonists: still more friends than foes.
Eur Respir J, 5 (1992), pp. 898-900
[93.]
M.A.B. Devoy, R.W. Fuller, J.D.B. Palmer.
Are there any detrimental effects on the use of inhaled long-acting beta-agonists in the treatment of asthma?.
Chest, 107 (1995), pp. 1116-1124
[94.]
G. Schultze-Werninghaus.
Multicenter 1-year trial of FM, a new long-acting beta 2-agonist, in chronic obstructive airway disease.
Lung, 169 (1990), pp. 83-89
[95.]
R.A. Pauwels, C.G. Löfdahl, D.S. Postma, A.E. Tattersfield, P. O’Byrne, P.J. Barnes, et al.
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET).
N Engl J Med, 337 (1997), pp. 1405-1411
[96.]
M. Sears.
Long-acting beta-agonists, tachyphylaxis and corticosteroids.
Chest, 109 (1996), pp. 862-863
[97.]
M. Weinberger.
Salmeterol for the treatment of asthma.
Ann Allergy Asthma Immunol, 75 (1995), pp. 209-211
[98.]
R. Dahl, J.S. Earnshaw, J.B. Palmer.
Salmeterol: a four week study of a long-acting betaadrenoceptor agonist for the treatment of reversible airways disease.
Eur Respir J, 4 (1991), pp. 1178-1184
[99.]
P. Wilding, M. Clark, J.T. Coon, S. Lewis, L. Rushton, J. Bennett, et al.
Effect of long-term treatment with SM on asthma control: a double blind, randomised crossover study.
Br Med J, 314 (1997), pp. 1441-1446
[100.]
G. Russell, D.A. Williams, P. Weller, J.F. Price.
Salmeterol xinafoate in children of high dose inhaled steroids.
Ann Allergy Asthma Immunol, 75 (1995), pp. 423-428
[101.]
G. Boyd, U.K. Study.
UK Study Group. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy.
Eur Respir J, 8 (1995), pp. 1494-1498
[102.]
A.J. Schreurs, H.E. Sinninghe Damsté, C.S. De Graaff.
Greefhorst APL. A dose-response study with FM Turbuhaler as maintenance therapy in asthmatic patients.
Eur Respir J, 9 (1996), pp. 1678-1683
[103.]
T. Van der Molen, D.S. Postma, M.O. Turner, B.M. Jong, J.L. Malo, K. Chapman, et al.
Effects of the long acting beta agonist FM on asthma control in asthmatic patients using inhaled corticosteroids The Netherlands and Canadian Formoterol Study Investigators.
Thorax, 52 (1997), pp. 535-539
[104.]
A. Ullman, N. Svedmyr.
SM, a new long acting inhaled beta-2 adrenoceptor agonist: comparison with salbutamol in asthmatic patients.
Thorax, 43 (1988), pp. 674-679
[105.]
M.F. Fitzpatrick, T. Mackay, H. Driver, N.J. Douglas.
Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.
Br Med J, 301 (1990), pp. 1365-1368
[106.]
P. Faurschou, A.M. Engel, Haanaes.
Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies.
Allergy, 49 (1994), pp. 827-832
[107.]
F.P. Maesen, J.J. Smeets, H.L. Gubbelmans, P.G. Zweeres.
Formoterol in the treatment of nocturnal asthma.
Chest, 98 (1990),
[108.]
J.F. Muir, L. Bertin, D. Georges.
Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial French Multicentre Study Group.
Eur Respir J, 5 (1992), pp. 1197-1200
[109.]
L. Fjellbirkeland, A. Gulsvik, J.B. Palmer.
The efficacy and tolerability of inhaled SM and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease.
Respir Med, 88 (1994), pp. 599-607
[110.]
M.P. Rutten van Mölken, P. Custers, E.K. Van Doorslaer, C.C. Jansen, L. Heurman, F.P. Maesen, et al.
Comparison of performance of four instruments in evaluation the effects of salmeterol on asthma quality of life.
Eur Respir J, 8 (1995), pp. 888-898
[111.]
A.L. Boner, E. Spezia, P. Piovesan, et al.
Inhaled formoterol in the prevention of exercise induced bronchoconstiction in asthmatic children.
Am J Respir Crit Care Med, 149 (1994), pp. 935-939
[112.]
J.P. Kemp, R.J. Dockhorn, W.W. Busse, et al.
Prolonged effect of inhaled salmeterol against exercise induced bronchospasm.
Am J Respir Crit Care Med, 150 (1994), pp. 1612-1615
[113.]
H. Booth, K. Fishwick, R. Harkawat, G. Devereux, D.J. Hendrick, E.H. Walters.
Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist SM in mold to moderate asthmatic patients.
Thorax, 48 (1993), pp. 1121-1124
[114.]
J.G. Maconochie, L.H. Denyer, H. Hassani.
Dose-related protection against histamine-induced bronchoconstriction by inhaled salmeterol.
Int J Clin Pharmacol Ther, 32 (1994), pp. 329-334
[115.]
A. Cartier, H. Ghezzo, J. Larchevêque, C. Trudeau, J.L. Malo.
Duration and magnitude of action of 50 and 100 mcg of inhaled salmeterol against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma.
J Allergy Clin Immunol, 92 (1993), pp. 488-492
[116.]
D. Nowak, R. Jorres, K.F. Rabe, et al.
Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.
Eur J Clin Pharmacol, 43 (1992), pp. 591-595
[117.]
E.H. Ramsdale, J. Otis, P.A. Kline, L.S. Gontovnick, F.E. Hargreave, P.M. O’Byrne.
Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist.
Am Rev Respir Dis, 143 (1991), pp. 998-1001
[118.]
K.F. Rabe, R. Jörres, D. Nowak, N. Beh, H. Magnussen.
Comparison of the effects of salmeterol and formotherol on airway tone and responsiveness over 24 hours in bronchial asthma.
Am Rev Respir Dis, 147 (1993), pp. 1436-1441
[119.]
M. Soler, L. Joos, C.T. Bolliger, S. Elsasser, A.P. Perruchoud.
Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine –and AMP– induced bronchoconstriction.
Eur Respir J, 7 (1994), pp. 1973-1977
[120.]
A.P. Greening, P.W. Ind, M. Northfield, G. Shaw.
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid.
Lancet, 344 (1994), pp. 219-224
[121.]
A. Woolcock, B. Lundback, N. Ringdal, L.A. Jacques.
Comparison of addition of SM to inhaled steroids with doubling of the dose of inhaled steroids.
Am J Respir Crit Care Med, 153 (1996), pp. 1481-1488
[122.]
S. Hummel, L. Lehtonen.
Comparison of oral-sparing by highdose and low-dose inhaled steroid in maintenance treatment of severe asthma.
Lancet, 340 (1992), pp. 1483-1487
[123.]
S.I. Wasserman, G.N. Gross, W.F. Schoenwetter, Z.M. Munk, K.M. Kral, A. Schaberg, et al.
A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma.
J Asthma, 33 (1996), pp. 265-274
[124.]
K. Alving, J. Lundberg, S.L. Nordvall.
Dose-dependent reduction of exhaled nitric oxide in asthmatic children by inhaled steroids.
Am J Respir Crit Care Med, 151 (1995), pp. A129
[125.]
C.-G. Lofdhal, K.F. Chung.
Long acting beta-adrenoceptor agonists: a new perspective in the treatment of asthma.
Eur Respir J, 4 (1991), pp. 218-226
[126.]
K. Tomioka, T. Yamada, H. Ida.
Anti-allergic activities of the beta-adrenoceptor stimulant formoterol (bd 40 a).
Arch Intern Pharmacodyn, 250 (1981), pp. 279-292
[127.]
P.R. Butchers, S.A. Cousins, C.J. Vardey.
Salmeterol: a potent and long acting inhibitor of the release of inflammatory and spasmogenie mediatrs from human lung.
Br J Pharmacol, 92 (1987), pp. 745
[128.]
B. Waldeck.
Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists.
Gen Pharmacol, 27 (1996), pp. 575-580
[129.]
G.P. Anderson, A. Linden, K.F. Rabe.
Why are long-acting betaadrenoceptor agonists long-acting?.
Eur Respir J, 7 (1994), pp. 569-578
[130.]
G.P. Anderson.
Formoterol: pharmacology, molecular basis of agonism and mechanism of long duration of a highly potent and selective beta2-adrenoreceptor agonist bronchodilator.
Life Sci, 52 (1993), pp. 2145-2160
[131.]
M. Johnson, P.R. Butchers, R.A. Coleman, A.T. Nials, P. Strong, M.J. Summer, et al.
The pharmacology of salmeterol.
Life Sci, 52 (1993), pp. 2131-2143
[132.]
A. Bergendal, A. Lindén, B.E. Skoogh, M. Gerspacher, G.P. Anderson, C.G. Löfdahl.
Extent of salmeterol medaited reassertion of relaxation in guinea-pig trachea pretreated with the aliphatic side chain structural analogues.
Br J Pharmacol, 117 (1996), pp. 1009-1015
[133.]
S.A. Green, A.P. Spasoff, R.A. Coleman, M. Johnson, S.B. Liggett.
Sustained activation of a G protein-coupled receptor via “anchored” agonist binding: molecular localization of the salmeterol exosite within the beta2-adrenergic receptor.
J Biol Chem, 271 (1996), pp. 24029-24035
[134.]
R.H. Moore, A. Khan, B.E. Dickey.
Long-acting inhaled β-agonists in asthma therapy.
Chest, 113 (1998), pp. 1095-1098
[135.]
A.E. Tattresfield.
Clinical pharmacology of long-acting betareceptor agoinsts.
Life Sci, 52 (1993), pp. 2161-2169
[136.]
R.B. Clark, C. Allal, J. Friedman, M. Johnson, R. Barber.
Stable activation and desentization of beta2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite.
Mol Pharmacol, 49 (1996), pp. 182-189
[137.]
B. January, A. Seibold, C. Allal, B.S. Whaley, B.J. Knoll, R.H. Moore, et al.
Salmeterol-induced desensitization, internelization and phosphorylation of the human beta-adrenoceptor.
Br J Pharmacol, 123 (1998), pp. 701-711
[138.]
A.T. Nials, D.I. Ball, P.R. Butchers, R.A. Coleman, A.A. Humbles, M. Johnson, et al.
Formoterol on airway smooth muscle and human lung must cells: a comparison with salbutamol and salmeterol.
Eur J Pharmacol, 251 (1994), pp. 127-135
[139.]
H. Lemoine, C. Overlack, A. Köhl, A. Worth, D. Reinhardt.
Formoterol. Fenoterol and salbutamol as partial agonists for relaxation of maximally contracted guinea-pig trachea: comparison of relaxation with receptor binding.
Lung, 170 (1992), pp. 163-180
[140.]
F.J. Rouz, B. Grandordy, J.S. Douglas.
Functional and binding characteristics of long-acting beta-agonists in lung and heart.
Am Respir Crit Care Med, 153 (1996), pp. 1489-1495
[141.]
G.P. Anderson.
Long acting inhaled beta-adrenoceptor agonists: the comparative pharmacology of formoterol and salmeterol.
Agents Action, 43 (1993), pp. 253-269
[142.]
E. Naline, Y. Zhang, Y. Qian, et al.
Relaxant effects and durations of actions of formoterol and salmeterol on the isolated human bronchus.
Eur Respir J, 7 (1994), pp. 914-920
Copyright © 2000. Sociedad Española de Neumología y Cirugía Torácica
